All topics

    Pillar 8 of 9

    Risk, Limits, and Critical Perspectives

    Psychedelics carry real risks: cardiac strain, dangerous drug interactions (especially with SSRIs, lithium, MAOIs, tramadol), psychological harm from challenging experiences, and triggering or worsening conditions like psychosis and bipolar disorder in vulnerable individuals. They are also not a universal solution: many people who try them experience little benefit, and integration of difficult experiences requires resources not everyone has. This pillar covers the contraindications, harm-reduction practices, and limits of current evidence honestly.

    In this pillar

    10 topics

    01

    Addiction and Misuse

    The genuinely low addiction potential of classical psychedelics, how this differs for MDMA and ketamine, and what the research on psychedelic-assisted treatment for other addictions suggests.

    02

    Challenging Experiences

    What challenging psychedelic experiences actually involve, who is more likely to have them, and the orientation that tends to be most useful - both during difficulty and in the integration that follows.

    03

    Contraindications

    The medical, psychiatric, and pharmacological conditions that make psychedelic use inadvisable - psychiatric history, medication interactions, cardiovascular considerations, and contextual factors that elevate risk.

    04

    Drug Interactions

    How psychedelics interact with medications and other substances, covering MAOIs, SSRIs, lithium, stimulants, and general safety principles.

    05

    Harm Reduction

    Practical strategies for reducing risks associated with psychedelic use, covering substance testing, preparation, trip sitting, environment, and medical contraindications.

    06

    HPPD and Persistent Perceptual Effects

    What HPPD actually involves - persistent visual changes following psychedelic use, how it is defined, its uncertain prevalence, proposed risk factors, and the limited treatment options.

    07

    Medicalization Critiques

    The serious critiques of turning psychedelic experiences into medical treatments - reductionism, individualization, access inequality, economic concentration, and indigenous knowledge appropriation.

    08

    Psychosis Risk

    The real and carefully documented risk of psychedelic-induced psychotic episodes, who is most at risk, what research screening protects against, and how to think about this risk honestly.

    09

    The Limits of Psychedelics

    What psychedelic medicines do not do - the real limits of these experiences, why profound sessions do not guarantee lasting change, and the conditions and individual variations that affect outcomes.

    10

    When Not to Use

    The circumstances - psychiatric, medical, and situational - in which the timing for a psychedelic experience is poor, and why "not now" is often more accurate than "never."

    Continue exploring

    Other pillars